Polarean Imaging Sells Xenon MRI System to NIH Clinical Center

The latest announcement is out from Polarean Imaging ( (GB:POLX) ).

Polarean Imaging has announced the sale of its Xenon MRI System to the National Institutes of Health (NIH) Clinical Center, marking the first direct purchase by the NIH. This acquisition will enhance research capabilities in lung imaging and respiratory conditions, positioning Polarean as a leader in innovative MRI techniques. The collaboration with the NIH is expected to advance studies on lung diseases and improve patient care, reinforcing Polarean’s impact on the medical imaging industry.

The most recent analyst rating on (GB:POLX) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.

Spark’s Take on GB:POLX Stock

According to Spark, TipRanks’ AI Analyst, GB:POLX is a Neutral.

Polarean Imaging’s overall stock score is primarily impacted by its challenging financial performance and bearish technical indicators. The negative valuation metrics further weigh down the score. Although recent corporate events are positive, they are not enough to offset the significant financial and technical challenges.

To see Spark’s full report on GB:POLX stock, click here.

More about Polarean Imaging

Polarean Imaging is a medical imaging technology company specializing in pulmonary medicine. It provides MRI-based solutions for visualizing lung function, addressing the needs of over 500 million patients with chronic respiratory diseases worldwide. The company has developed the FDA-approved XENOVIEW®, a hyperpolarized Xenon MRI inhaled contrast agent, and is committed to advancing non-invasive, radiation-free pulmonary functional MRI technology.

Average Trading Volume: 2,770,620

Technical Sentiment Signal: Sell

Current Market Cap: £6.94M

For a thorough assessment of POLX stock, go to TipRanks’ Stock Analysis page.